在转移性激素敏感性前列腺癌男性的雄激素剥夺治疗中加入阿比特龙:系统综述与Meta分析
该系统综述与Meta分析评估在转移性激素敏感性前列腺癌(mHSPC)患者的雄激素剥夺治疗(ADT)基础上加用醋酸阿比特龙联合泼尼松/泼尼松龙(AAP)的疗效。纳入LATITUDE和STAMPEDE两项试验(占全部随机化患者的82%),结果显示AAP+ADT较ADT显著降低死亡风险38%(HR=0.62,95%CI 0.53-0.71,p=0.55×10^-10),3年OS绝对改善14%;临床/影像学PFS风险降低55%(HR=0.45,95%CI 0.40-0.51,p=0.66×10^-36),3年绝对改善28%。AAP+ADT组III-IV级急性心脏、血管和肝脏毒性更多,但其他毒性或死亡无增加。作者认为AAP+ADT是mHSPC的临床有效治疗选择,为首次治疗的患者提供了多西他赛的替代方案。
要点
- AAP+ADT较ADT显著降低死亡风险38%(HR=0.62,95%CI 0.53-0.71),3年OS绝对改善14%。
- AAP+ADT较ADT显著降低临床/影像学PFS风险55%(HR=0.45,95%CI 0.40-0.51),3年绝对改善28%。
- AAP+ADT组III-IV级急性心脏、血管和肝脏毒性更多,但其他毒性或死亡无增加。
核心结论
- 在mHSPC男性的ADT中加入AAP是临床有效的治疗选择,为首次治疗的患者提供了多西他赛的替代方案。
研究设计与样本
- 采用自适应Meta分析框架(FAME),在试验结果报告前启动综述,与试验研究者合作预判合格试验结果出现时间,检索多个来源比较AAP+ADT与ADT的试验。
- 从试验团队直接获取主要结局总生存(OS)、次要结局临床/影像学无进展生存(PFS)及III-IV级和V级毒性的结果。
- 采用固定效应Meta分析合并AAP+ADT对OS和PFS的风险比(HR)、对急性毒性的Peto比值比(Peto OR)及按患者亚组对OS影响的交互作用HR。
- 识别出3项合格试验,其中1项(PEACE-1,NCT01957436)仍在招募;纳入分析的2项试验(LATITUDE,NCT01715285;STAMPEDE,NCT00268476)代表了全部随机分配至AAP+ADT versus ADT(两组均未使用多西他赛)患者的82%。
主要发现
- AAP+ADT较ADT显著降低死亡风险38%(HR=0.62,95%CI 0.53-0.71,p=0.55×10^-10),对应3年OS绝对改善14%。
- AAP+ADT较ADT显著降低临床/影像学PFS风险55%(HR=0.45,95%CI 0.40-0.51,p=0.66×10^-36),对应3年绝对改善28%。
- 按Gleason总和评分、体能状态或淋巴结状态未见OS获益差异的证据,但获益大小可能随年龄变化。
- AAP+ADT组III-IV级急性心脏、血管和肝脏毒性更多,但其他毒性或死亡无增加。
关键数值与推荐
- AAP+ADT较ADT的OS HR=0.62(95%CI 0.53-0.71,p=0.55×10^-10),3年OS绝对改善14%。
- AAP+ADT较ADT的临床/影像学PFS HR=0.45(95%CI 0.40-0.51,p=0.66×10^-36),3年绝对改善28%。
- 按Gleason总和评分、体能状态或淋巴结状态未见OS获益差异的证据,但获益大小可能随年龄变化。
- AAP+ADT组III-IV级急性心脏、血管和肝脏毒性更多,但其他毒性或死亡无增加。
临床怎么用
- 作者认为,在ADT中加入AAP是mHSPC男性的临床有效治疗选择,为首次开始治疗的患者提供了多西他赛的替代方案。
局限性
- 1项合格试验(PEACE-1)仍在招募,结果不可用。
- 各试验间PFS定义存在差异。
- 未来研究需要解决这两种药物中哪一种或二者联合最为有效,以及适用于哪些患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. METHODS: Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III-IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis. FINDINGS: We identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53-0.71, p = 0.55 × 10-10), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40-0.51, p = 0.66 × 10-36) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III-IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death. INTERPRETATION: Adding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom.
引用
- Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017. PMID: 28800492. doi:10.1016/j.ejca.2017.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。